3rd Quarter - Report
LEAVITT PARTNERS, LLC for SICKLE CELL DISEASE PARTNERSHIP
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Income
$50,000
Expenses
—
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report (this page) | Oct 20, 2026 | $50,000 | Replaced |
| 3rd Quarter - Amendment | Oct 20, 2026 | $50,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Sickle cell disease focused legislation, federal funding, and federal programs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT CLAYTON ALSPACH | Chief Health Counsel for Chairman - House E&C Committee (E&C);Counsel - E&C, Clerk - E&C, and Paid Intern - E&C |
| VICTORIA GEMME | — |
| JOSH TRENT | Chief Health Counsel for Chairman - House E&C Committee (E&C); Deputy Chief Health Counsel - E&C; Professional Staff - E&C; Health Care Policy Advisor - Senate; Deputy Director Office of Refugee Resettlement HHS; WH Office of Presidential Personnel |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.